ClinicalTrials.gg
Not yet recruitingNCT06804863Updated Feb 3, 2025

Regret Emotion After Thyroidectomy in Low-Risk Papillary Thyroid Cancer

An interventional study of Postoperative Regret Reduction through Immediate Quality of Life Intervention in Thyroid Cancer and Regret, sponsored by West China Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-03.

Primary conditionThyroid Cancer, PapillaryRegistry: Thyroid NeoplasmsReclassifiedWhy we changed it
Registry
Thyroid Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Thyroid Cancer, Papillary
Why
  1. The study's title name Thyroid Cancer, Papillary, a narrower term within Thyroid Neoplasms.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by West China Hospital · Not applicable, Interventional, and Health services research

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies in Thyroid Cancer, Papillary with a site in China — 24 open to participants now, 25 under way, 1 of them phase 3. Thyroid Cancer, Papillary · China.

Planned enrollment
3rd of 21
600 · median 170
Started
2025
with 4 others
No phase
14 of 40
7 open now
Primary completion
2027-05
later than 16 of 24 live
Registered
34th of 40
by date
Lead sponsor
3 of 40
West China Hospital

Among the 40 studies in Thyroid Cancer, Papillary with a site in China, this one is the 3rd largest by planned enrollment of the 21 interventional ones that give a count, is one of 5 that started in 2025, is one of 14 with no phase, reaches primary completion later than 16 of the 24 other live ones, and was the 34th registered.

Thyroid Cancer, Papillary

187 studies on the registry are indexed under Thyroid Cancer, Papillary; 50 are open to participants now.

Browse Thyroid Cancer, Papillary studies →

Open to participants now

24 of the 40 studies in Thyroid Cancer, Papillary with a site in China are open now. Recruiting first, the newest first:

19 more — sign in →

All 24 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 31 Thyroid Cancer, Papillary studies recruiting now, 18 (58%) set no upper age limit and 8 (26%) stop at 75 or younger; 13 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Thyroid Cancer, Papillary with a site in China, or all of them as a file.
02

Study summary

This randomized, active-controlled, non-inferiority trial is scheduled to begin in May 2025 and will continue until June 2027. Inclusion criteria: (1) Patients with low-risk papillary thyroid cancer without lymph node metastasis who have undergone thyroid surgery (including both laparoscopic and open surgery) at the Department of Thyroid Surgery, West China Hospital, Sichuan University, (2) Aged between 18 and 90 years, (3) Chinese-speaking, (4) Capable of completing questionnaires and using a mobile phone and internet for intervention purposes, (5) No history of psychiatric disorders or use of psychotropic medications, (6) Voluntary participation and signing of an informed consent form. Exclusion criteria: (1) Patients with cervical lymph node metastasis, (2) Incomplete baseline data, (3) Uncontrolled chronic diseases, (4) Patients with other cancers. Online outpatient follow-up will be conducted by doctors from the Department of Thyroid Surgery at West China Hospital. One study participant will contact the patient, introduce the study, and obtain the informed consent form from willing participants. The research team members responsible for patient contact, registration, and randomization include the principal investigator, study coordinator, and specially trained research assistants. The management of the intervention group patients will be carried out by doctors from the corresponding departments. According to the protocol, patients assigned to online visits will switch to offline visits and exit the clinical trial under the following circumstances: (1) unresolved technical issues, (2) inability to perform a comprehensive assessment, (3) patient request for withdrawal. Other cross-cutting reasons include patient requests and scheduling conflicts. Baseline data (including age, gender, ethnicity, address, occupation), tumor-related information (including tumor histology, maximum tumor diameter, capsular invasion status, number of lymph node metastases), and surgical method will be collected from the hospital's information department. Participants will be given the DRS scale upon discharge and every two months thereafter to assess their regret status. For patients with high regret (DRS score >25), a QoL scale will be further distributed to collect information about their quality of life. The REDCap randomization module will be used, and block randomization will be computer-generated with block sizes of 6 and 9, in a 1:1 ratio, to allocate patients to either the intervention or control group. The allocation sequence will be concealed, and the randomized results will be extracted by an independent data collection team. If intervention group patients need to complete the QoL scale, after completion, the doctor from the department corresponding to the factor with the highest score (i.e., the factor most closely related to the patient's regret state) will receive an SMS notification and will be required to contact the patient by phone or SMS within 24 hours to provide the intervention. If contact is not established within 24 hours of the intervention phase, the research participant will call the patient up to two times to clarify the reason.

03

Conditions studied

  • Thyroid Cancer
  • Regret

Browse trials for

Keywords

  • Papillary thyroid cancer
  • regret
  • active intervention
  • prognosis
04

In context

Thyroid Cancer, Papillary Reclassified

187 studies on the registry are indexed under Thyroid Cancer, Papillary; 50 are open to participants now.

This study's planned enrollment of 600 is above the median of 41 across 114 interventional studies indexed under Thyroid Cancer, Papillary.

Browse Thyroid Cancer, Papillary studies →

Lead sponsor

West China Hospital is the lead sponsor of 503 studies on the registry; 247 are open to participants now.

Compared within Thyroid Cancer, Papillary, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Thyroid Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with low-risk papillary thyroid cancer without lymph node who have undergone thyroid surgery,
  2. Aged between 18 and 90 years,
  3. Chinese-speaking,
  4. Capable of completing questionnaires and using a mobile phone and internet for intervention purposes,
  5. No history of psychiatric disorders or use of psychotropic medications,
  6. Voluntary participation and signing of an form.

Exclusion criteria

Exclusion Criteria:

  1. Patients with cervical lymph node ,
  2. Incomplete baseline data,
  3. Uncontrolled chronic diseases,
  4. Patients with other cancers.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
600 participants (estimated)

Study arms

  • Experimental
    Intervening in patients with postoperative regret emotion.

    For the worst postoperative quality of life factors reported by patients, specialized doctors will provide immediate guidance and management via SMS or phone.

    Behavioral: Postoperative Regret Reduction through Immediate Quality of Life Intervention

  • No intervention
    Only the patients' postoperative regret levels and quality of life scores will be collected.

    Only the patients' postoperative regret levels and quality of life scores will be collected, without any additional interventions.

Interventions

  • BehavioralPostoperative Regret Reduction through Immediate Quality of Life Intervention

    Immediate intervention of the major impaired quality of life factors postoperatively to reduce patients' postoperative regret.

07

What researchers measure

Primary outcomes

  1. Clarifying the impact of immediate intervention on patients' postoperative regret psychology.

    Over a 12-month period after the start of the study, observe the declining trend of regret scores in patients who received immediate intervention compared to the control group.

    Time frame: From enrollment to the end of follow-up at 12 months

Secondary outcomes

  1. Main Factors Affecting Postoperative Regret in Low-Risk PTC Patients

    Over a 12-month period after the start of the study, evaluate patients' quality of life in different aspects following thyroid cancer surgery at each time point using the thyroid cancer-specific Quality of Life (QoL) scale.

    Time frame: From enrollment to the end of follow-up at 12 months

08

Study locations

1 site
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2025; primary completion for May 2027, 24 months later.

Of 26 interventional studies with no phase under Thyroid Cancer, Papillary, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 71. This study's planned 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2025
First posted
Feb 3, 2025
StartEst.
May 1, 2025
Primary completionEst.
May 1, 2027
CompletionEst.
May 30, 2027
Last update
Feb 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06804863
Responsible party
Xinyi Wang (Dr, Sichuan University) — Principal investigator
First posted
Feb 3, 2025
Start date
May 1, 2025 (estimated)
Primary completion
May 1, 2027 (estimated)
Completion
May 30, 2027 (estimated)
Last update
Feb 3, 2025

Study contacts

Jianyong Lei, Md
Contact
leijianyong@scu.edu.cn
86-19983137992

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion